BU-NOT-SET

CONTACT US
Brexit: What’s next for UK pharma?
  • Industry trends
Eyes
Insight
Navigating approval filings choppy international waters
  • Drug substance
Eyes
Insight
Regulatory requirements for drug substances
  • Drug substance
Product check
Insight
The QbD approach: Key advantages in clinical and commercial phases
  • Analytical chemistry
Lab
Insight
Sustainability report 2020
  • Sustainability
Report
Report
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
  • Drug substance
Man at poster
Poster
Recipharm Analytical Solutions™
  • Analytical chemistry
Icon
Fact sheet
Impurity identification
  • Analytical chemistry
Woman inserting vials in machine
Fact sheet
Stability studies
  • Analytical chemistry
hand holding vials plate
Fact sheet
Insight
  • Manufacturing
Recipharm launches new virtual inspection and audit tool for customers, in light of COVID-19 outbreak
Brochure
  • Corporate
Recipharm 25 years
Fact sheet
  • Drug substance
API product list
Insight
  • Drug substance
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
Insight
  • Industry trends
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
Insight
  • Corporate
Women in leadership
Insight
  • Drug product
The state of the oral solid dose development and manufacturing market
Insight
  • Drug substance
Characterising APIs is Essential for Combo Drug Formulations
Insight
  • Analytical chemistry
Outsourcing stability testing